ET-STEM

Phase 1Small molecule

SSamsung Medical Center

ET-STEM is one of 12 small molecule programs targeting Frontotemporal Dementia. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Frontotemporal DementiaActive, not recruiting

Frontotemporal DementiaPhase 1

Active, not recruiting

Competition

Competitive Landscape

15 competitors in Frontotemporal Dementia

#DrugCompanyPhaseTrials

Namenda

AbbVie

Approved

1 2

Celexa

AbbVie

Approved

1 3

Gocovri

GGrupo Espanol de Tumores Neuroendocrinos

Approved

1 4

Rapamune

PPrism Pharmaceuticals

Rayos

Glucophage

Brintellix

1 8

Medrol

Pfizer

Phase 1

1 9

NS101

NNeuracle Science Co., LTD.

Phase 2

1 10

Lumbar Puncture

Takeda

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 1Active, not recruiting

Frontotemporal Dementia

NCT05315661

Clinical

Trials by Indication[1]

Frontotemporal Dementia1 trial

The Safety and The Efficacy Evaluation of ET-STEM in Patients With Frontotemporal Dementia

Active, not recruiting·SSamsung Medical Center·Phase 1·NCT05315661·12 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for ET-STEM. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — ET-STEM compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for ET-STEM. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Samsung Medical Center company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: SSamsung Medical Center

ET-STEM

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Frontotemporal Dementia1 trial

References

Drug Info

Quick Facts

Related News